A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (NCT07102381)

🧪 Interventions in This Study

• Zanidatamab (DRUG)
• Paclitaxel (DRUG)
• Docetaxel (DRUG)
• Carboplatin (DRUG)
• Trastuzumab (DRUG)
• Pertuzumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (35 Sites)

Showing the first 25 of 35 sites.

• Oncology Institute — Long Beach, California
• Cancer & Blood Research Center — Los Alamitos, California
• Rocky Mountain Cancer Centers — Denver, Colorado
• Holy Cross Hospital — Fort Lauderdale, Florida
• The Oncology Institute — Lakeland, Florida
• Accellacare of McFarland — Ames, Iowa
• LSU Health Sciences Center — Shreveport, Louisiana
• New England Cancer Specialists — Scarborough, Maine
• Maryland Oncology Hematology — Laurel, Maryland
• Henry Ford Hospital — Detroit, Michigan
• Cancer Partners of Nebraska — Lincoln, Nebraska
• Nebraska Cancer Specialists — Omaha, Nebraska
• Astera Cancer Care (Formerly Regional Cancer Care Associates) — East Brunswick, New Jersey
• Medical Oncology Hematology Associates — Newark, New Jersey
• The University of New Mexico — Albuquerque, New Mexico
• Hematology Oncology Associates of Central New York — Camillus, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Levine Cancer — Charlotte, North Carolina
• Sarah Cannon Research Institute (Nashville) — Nashville, Tennessee
• Texas Oncology DFW — Dallas, Texas
• The University of Texas Southwestern Medical Center — Dallas, Texas
• Texas Oncology Gulf Coast — Houston, Texas
• UT Health San Antonio, Mays Cancer Center — San Antonio, Texas
• Virginia Cancer Specialists — Fairfax, Virginia
• Virginia Oncology Associates — Norfolk, Virginia

📞 Contact the Study Coordinator

Phone: (215) 832-3750

Email: ClinicalTrialDisclosure@JazzPharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HER2-positive Breast Cancer

• Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease — Tampa, Florida
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] — Los Angeles, California
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — Plantation, Florida
• PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer — Boston, Massachusetts
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Mobile, Alabama
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Stamford, Connecticut

Explore by condition: All HER2-positive Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.